[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovée JV: The clinical approach towards chondrosarcoma. Oncologist; 2008 Mar;13(3):320-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical approach towards chondrosarcoma.
  • This review provides an overview of the histopathology, classification, diagnostic procedures, and therapy of skeletal chondrosarcoma.
  • Conventional chondrosarcomas can be categorized according to their location in bone into central, peripheral, and juxtacortical chondrosarcomas.
  • Rare subtypes of chondrosarcoma, including dedifferentiated, mesenchymal, and clear cell chondrosarcoma, are discussed as well.
  • Magnetic resonance imaging is necessary to delineate the extent of the intraosseous and soft tissue involvement preoperatively.
  • Computed tomography is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization.
  • Wide, en-bloc excision is the preferred surgical treatment in intermediate- and high-grade chondrosarcoma.
  • In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control.
  • Chondrosarcomas are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in attempts to achieve local control after incomplete resection.
  • Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma.
  • Potential new systemic treatment targets are being discussed.
  • [MeSH-major] Bone Neoplasms / therapy. Chondrosarcoma, Mesenchymal / therapy
  • [MeSH-minor] Humans. Mesoderm / pathology. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncologist. 2008 May;13(5):618
  • (PMID = 18378543.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 91
  •  go-up   go-down


2. Dantonello TM, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, Schneider DT, Klingebiel T, Bielack SS, Koscielniak E, CWS study group, COSS study group: Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer; 2008 Jun;112(11):2424-31
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups.
  • BACKGROUND: Mesenchymal chondrosarcoma (MCS) is a rare tumor with a strong tendency toward late recurrences leading to reported 10-year survival rates below 50%.
  • The recommended treatment is resection with wide margins; the effectiveness of chemo- and radiotherapy remain poorly defined.
  • As reports about MCS in young patients are scarce, treatment and outcomes of children/adolescents/young adults in the CWS and COSS studies were investigated.
  • METHODS: Since 1977, 15 of >7000 CWS and COSS patients <or=25 years had a confirmed diagnosis of MCS.
  • Thirteen individuals received chemotherapy, 6 were irradiated.
  • Four recurrences occurred, all within 4 years from diagnosis (3 local, 1 combined; 2 of these in irradiated patients).
  • Seven of 8 patients whose tumors were completely resected during primary treatment, but only 4 of 7 patients with incomplete surgery survived disease-free.
  • CONCLUSIONS: This series of 15 MCS differs from others: the median age was young, most tumors were extraosseous, most patients received chemotherapy, and the outcome was better than published.
  • Treating MCS according to standard multimodal soft tissue/bone sarcoma regimens is proposed.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18438777.001).
  • [ISSN] 1097-0142
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Zibis AH, Wade Shrader M, Segal LS: Case report: Mesenchymal chondrosarcoma of the lumbar spine in a child. Clin Orthop Relat Res; 2010 Aug;468(8):2288-94
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Mesenchymal chondrosarcoma of the lumbar spine in a child.
  • BACKGROUND: Chondrosarcomas of the spine constitute 4% to 10% of all primary spinal bone tumors and approximately 70% of the cases occur during the second or third decade of life.
  • Mesenchymal chondrosarcoma is a rare aggressive variant of chondrosarcoma.
  • The prognosis of mesenchymal chondrosarcoma is usually poor with a tendency for late local recurrence and metastasis.
  • CASE DESCRIPTION: We describe a case of primary mesenchymal chondrosarcoma affecting the L5 vertebra of a 9-year-old girl.
  • The patient underwent a staged circumferential resection of the tumor after three rounds of neoadjuvant chemotherapy.
  • The patient had additional chemotherapy and radiation therapy as an intralesional margin was achieved during the procedure.
  • LITERATURE REVIEW: We identified only four previously published cases of spinal mesenchymal chondrosarcoma in childhood, two of which had relatively early recurrence and poor survival, and two survived but with only short followup.
  • PURPOSES AND CLINICAL RELEVANCE: As the clinical and radiographic findings of mesenchymal chondrosarcoma are nonspecific, the diagnosis of this rare tumor requires careful histopathologic review of the specimens.
  • We suggest the differential diagnosis of every primary intraspinal tumor include tumors of mesenchymal origin.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Lumbar Vertebrae / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Neoadjuvant Therapy. Remission Induction. Spinal Neoplasms. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Orthop (Belle Mead NJ). 2001 Apr;30(4):329-32 [11334455.001]
  • [Cites] Curr Treat Options Oncol. 2009 Apr;10(1-2):94-106 [19238552.001]
  • [Cites] Spine (Phila Pa 1976). 1978 Sep;3(3):202-9 [715548.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):149-57 [7350999.001]
  • [Cites] Clin Orthop Relat Res. 1981 Jul-Aug;(158):144-8 [7273513.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1230-7 [6825046.001]
  • [Cites] Neuroradiology. 1984;26(4):323-7 [6462441.001]
  • [Cites] Neurosurg Rev. 1987;10(4):311-4 [3506147.001]
  • [Cites] Surg Neurol. 1989 Jan;31(1):54-7 [2645674.001]
  • [Cites] Surg Neurol. 1989 Jun;31(6):470-2 [2718090.001]
  • [Cites] J Bone Joint Surg Am. 1989 Sep;71(8):1158-65 [2777842.001]
  • [Cites] J Magn Reson Imaging. 1991 Jan-Feb;1(1):93-5 [1802137.001]
  • [Cites] Skeletal Radiol. 1993;22(5):362-6 [8372365.001]
  • [Cites] J Neurosurg. 1994 May;80(5):928-30 [8169637.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):150-3 [7671456.001]
  • [Cites] Cancer. 1996 May 1;77(9):1884-91 [8646689.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(11):1261-6 [8980727.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1997 Apr;26(4):279-82 [9113295.001]
  • [Cites] Cancer. 1959 Nov-Dec;12:1142-57 [14416919.001]
  • [Cites] Cancer. 2008 Jun;112(11):2424-31 [18438777.001]
  • [Cites] Cancer. 1971 Sep;28(3):605-15 [5096926.001]
  • (PMID = 20300902.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2895837
  •  go-up   go-down


Advertisement
4. Huang KF, Tzaan WC, Lin CY: Primary intraspinal mesenchymal chondrosarcoma: a case report and literature review. Chang Gung Med J; 2003 May;26(5):370-6
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraspinal mesenchymal chondrosarcoma: a case report and literature review.
  • Mesenchymal chondrosarcomas are rare malignant tumors of the bone and soft tissue.
  • Extraskeletal mesenchymal chondrosarcomas, especially those that arise in the central nervous system, are even rarer.
  • Therapeutic experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • Microscopic examination and immunohistochemical studies confirmed the diagnosis of mesenchymal chondrosarcoma.
  • Spinal irradiation and chemotherapy were also administered for prevention of local recurrence and metastasis.
  • Herein, we review the 22 cases of primary intraspinal mesenchymal chondrosarcomas in the literature and discuss their clinical presentations, pathology, imaging studies, treatments, and outcomes.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Spinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12934855.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 18
  •  go-up   go-down


5. Mohammadinezhad C: Chondrosarcoma of the jaw. J Craniofac Surg; 2009 Nov;20(6):2097-100
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondrosarcoma of the jaw.
  • Chondrosarcoma of the maxillofacial region is a rare tumor.
  • The classification of this tumor is based on histologic grades (1, 2, or 3) or variant including clear cell, differentiated, myxoid, and mesenchymal chondrosarcomas.
  • However, histologic differentiation between this tumor and other relevant bone tumors is fairly difficult.
  • Recently, molecular and genomic studies thought to be useful tools in a more definite diagnosis, accurate treatment, and quality of life of patients.
  • The most acceptable choice of treatment of the chondrosarcoma is wide resection.
  • Radiotherapy and chemotherapy as an adjunctive or palliative treatment remain controversial.
  • However, lifelong follow-up is essential because chondrosarcoma shows a high incidence of local recurrence as well as regional and distant metastasis more than 2 decades later.
  • This study presents 2 cases of chondrosarcoma with a long-term follow-up.
  • [MeSH-major] Chondrosarcoma / pathology. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881362.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Gorelik B, Ziv I, Shohat R, Wick M, Hankins WD, Sidransky D, Agur Z: Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res; 2008 Nov 1;68(21):9033-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.
  • The paucity of clinical treatment data on rare tumors, such as mesenchymal chondrosarcoma (MCS), emphasizes the need in theranostic tools for these diseases.
  • We put forward and validated a new theranostic method, combining tumor xenografts and mathematical models, and used it to suggest an improved treatment schedule for a particular MCS patient.
  • The pharmacokinetics and pharmacodynamics of six drugs were modeled, with model variables being adjusted by patient-specific chemosensitivity tests.
  • The xenografted animals were treated by various monotherapy and combination schedules, and the MCS xenograft model was computer simulated under the same treatment scenario.
  • The mathematical model for xenograft growth was then up-scaled to retrieve the MCS patient's tumor progression under different treatment schedules.
  • Further validation of this conclusion, and the theranostic method we provide, may facilitate personalization of solid cancer pharmacotherapy.

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1985 Jan;156(1):271-6 [3880704.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1085-90 [1627380.001]
  • [Cites] Biosystems. 1992;26(4):231-7 [1627734.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(6):469-76 [1394803.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Mutat Res. 1993 Aug;292(1):17-24 [7688093.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6446-51 [7987841.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):19761-6 [7544346.001]
  • [Cites] Drug Metab Dispos. 1995 Oct;23(10):1008-21 [8654187.001]
  • [Cites] J Pharm Sci. 1996 Feb;85(2):232-9 [8683454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8761-6 [9238051.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Acta Oncol. 1998;37(3):247-52 [9677095.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):382-7 [9703287.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):159-67 [15618001.001]
  • [Cites] Bull Math Biol. 2005 Jan;67(1):79-99 [15691540.001]
  • [Cites] J Theor Biol. 2005 Jun 7;234(3):311-27 [15784267.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7293-300 [16849579.001]
  • [Cites] Clin Colorectal Cancer. 2006 Sep;6(3):214-8 [17026791.001]
  • [Cites] Thromb Haemost. 2007 Jan;97(1):99-108 [17200776.001]
  • [Cites] Oral Oncol. 2007 Nov;43(10):970-5 [17681487.001]
  • [Cites] Cancer Immunol Immunother. 2008 Mar;57(3):425-39 [17823798.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):583-7 [16919884.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2444-53 [3697943.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1528-34 [10789719.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Jun;280(6):C1367-74 [11350731.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):518-27 [11809704.001]
  • [Cites] Anticancer Drugs. 2002 Jul;13(6):583-93 [12172503.001]
  • [Cites] Br J Ophthalmol. 2003 Jan;87(1):101-6 [12488272.001]
  • [Cites] Angiogenesis. 2002;5(3):203-14 [12831061.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):683-91 [14616973.001]
  • [Cites] Diabetes. 2004 Apr;53(4):1104-10 [15047628.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 5):25-30 [15199529.001]
  • [Cites] Trends Pharmacol Sci. 2004 Oct;25(10):536-42 [15380938.001]
  • [Cites] Crit Rev Bioeng. 1981;5(4):273-322 [7023829.001]
  • [Cites] Cancer Res. 1983 Jan;43(1):258-64 [6571706.001]
  • [ErratumIn] Cancer Res. 2008 Dec 1;68(23):10005
  • (PMID = 18974149.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084986-01; United States / NCI NIH HHS / CA / U01 CA084986; United States / NCI NIH HHS / CA / U01 CA084986-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS282356; NLM/ PMC3098452
  •  go-up   go-down


7. Inenaga C, Morii K, Tamura T, Tanaka R, Takahashi H: Mesenchymal chondrosarcoma of the sellar region. Acta Neurochir (Wien); 2003 Jul;145(7):593-7; discussion 597
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma of the sellar region.
  • BACKGROUND: It is known that, although rare, mesenchymal chondrosarcoma can originate intracranially.
  • CLINICAL PRESENTATION: We report a case of mesenchymal chondrosarcoma in a 21-year-old man who presented with double vision, right blepharoptosis and facial pain.
  • Upon initial admission, no endocrinological abnormalities were found, and computed tomography and magnetic resonance imaging revealed a mass with calcification in the sella and right cavernous sinus.
  • INTERVENTION: For this malignant tumour, three surgical resections, two sessions of gamma-knife radiosurgery, one session of fractional irradiation, and one cycle of chemotherapy were performed, resulting in only brief arrest of the tumour growth.
  • The undifferentiated small cells showed immunoreactivity for vimentin and ultrastructural features suggesting a mesenchymal origin.
  • CONCLUSION: Although malignant tumours in the sellar region are rare, they should be considered in the differential diagnosis of various sellar tumours typified by non-functioning pituitary adenoma, and mesenchymal chondrosarcoma is one possible candidate.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Sella Turcica / pathology

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12910404.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


8. Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E, Ferrari S: Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori; 2007 Sep-Oct;93(5):423-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution.
  • BACKGROUND: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC).
  • Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute.
  • METHODS: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients).
  • A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9).
  • In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008).
  • CONCLUSIONS: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS.
  • Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma, Mesenchymal / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038872.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kaur A, Kishore P, Agrawal A, Gupta A: Mesenchymal chondrosarcoma of the orbit: a report of two cases and review of the literature. Orbit; 2008;27(1):63-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma of the orbit: a report of two cases and review of the literature.
  • Mesenchymal chondrosarcoma, an uncommon lesion in bone and extraskeletal tissue, is extremely rare in the orbit.
  • Two cases of orbital mesenchymal chondrosarcoma in young adults presenting with proptosis and diminution of vision are reported.
  • The diagnosis was established by histopathological examination in both cases, which showed undifferentiated mesenchymal cells with islands of cartilage.
  • Both patients underwent exenteration followed by chemotherapy and radiation therapy and are alive with healthy orbits after two years of follow-up.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Neoplasm Recurrence, Local / therapy. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Female. Humans. Male. Orbit Evisceration. Radiotherapy, Adjuvant. Reoperation. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307151.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  • [Number-of-references] 11
  •  go-up   go-down


10. La Spina M, Dollo C, Giangaspero F, Bertolini P, Russo G: Intracranial mesenchymal chondrosarcoma with osteoid formation: report of a pediatric case. Childs Nerv Syst; 2003 Sep;19(9):680-2
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial mesenchymal chondrosarcoma with osteoid formation: report of a pediatric case.
  • A presumptive preoperative diagnosis of meningioma was made.
  • Histologically the neoplasms had the classic features of a mesenchymal chondrosarcoma associated with the focal presence of osteoid matrix.
  • DISCUSSION: Clinical features, therapeutic approaches and prognosis of this rare tumour are discussed with regard to the known 30 cases in the literature.
  • [MeSH-major] Bone Neoplasms / complications. Chondrosarcoma, Mesenchymal / complications. Osteoma, Osteoid / etiology
  • [MeSH-minor] Adolescent. Drug Therapy. Female. Headache / etiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Radiotherapy. Tomography, X-Ray Computed. Vomiting / etiology

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2000 Sep-Oct;7(5):1041-7 [10948336.001]
  • [Cites] No Shinkei Geka. 1981 Jun;9(7):843-8 [7266768.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):370-4 [10797365.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1327-35 [10751358.001]
  • [Cites] Br J Neurosurg. 2001 Oct;15(5):419-24 [11708546.001]
  • (PMID = 12700920.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Seidl RO, Gerein V, Vogel HJ, Ernst A: [Mesenchymal chondrosarcomas of the facial skull]. HNO; 2001 Sep;49(9):744-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesenchymal chondrosarcomas of the facial skull].
  • [Transliterated title] Mesenchymale Chondrosarkome des Gesichtschädels.
  • A 13-year-old girl suffered from a mesenchymal chondrosarcoma of the left maxilla.
  • The therapeutic options and the prognosis for this disease are described with respect to the currently known 72 cases in the literature.
  • Mesenchymal chondrosarcomas are rare tumors of the bone and soft tissue.
  • Radiological criteria for the identification of this type of tumor include focal ossification areas which are accompanied by non-calcified regions.
  • Complete surgical removal of the tumor is the therapy of choice.
  • Pre- and postoperative chemotherapy can have a beneficial effect.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / radiography. Maxillary Neoplasms / radiography
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Maxilla / pathology. Maxilla / radiography. Maxilla / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11593777.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Matsuda Y, Sakayama K, Sugawara Y, Miyawaki J, Kidani T, Miyazaki T, Tanji N, Yamamoto H: Mesenchymal chondrosarcoma treated with total en bloc spondylectomy for 2 consecutive lumbar vertebrae resulted in continuous disease-free survival for more than 5 years: case report. Spine (Phila Pa 1976); 2006 Apr 15;31(8):E231-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma treated with total en bloc spondylectomy for 2 consecutive lumbar vertebrae resulted in continuous disease-free survival for more than 5 years: case report.
  • STUDY DESIGN: A case report of an extremely rare malignant spinal tumor successfully treated with total en bloc spondylectomy and chemotherapy.
  • SUMMARY OF BACKGROUND DATA: Primary mesenchymal chondrosarcoma in the spine is extremely rare.
  • There were no reports of this tumor being treated with spondylectomy to achieve total surgical resection with a wide margin followed by chemotherapy.
  • Magnetic resonance imaging and computerized tomography showed an osteosclerotic tumor of the lumbar vertebrae.
  • Tc-99m HMDP bone scintigraphy was positive, but thallium-201 scintigraphy and gallium scintigraphy were negative.
  • The patient was diagnosed as having chondrosarcoma based on biopsy findings.
  • However, the postoperative pathologic diagnosis was extremely difficult because the patient was initially suspected to have osteosarcoma, but the final diagnosis was mesenchymal chondrosarcoma.
  • CONCLUSIONS: To our knowledge, we reported the first case of mesenchymal chondrosarcoma occurring from the lumbar spine treated with total en bloc spondylectomy and chemotherapy.
  • Although the effect of chemotherapy on the final results could not be clearly determined, considering that at least continuous disease-free survival was achieved, it is highly likely that chemotherapy contributed to the favorable results.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / surgery. Lumbar Vertebrae / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622368.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE: The clinical management of chondrosarcoma. Curr Treat Options Oncol; 2009 Apr;10(1-2):94-106
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical management of chondrosarcoma.
  • Surgical resection represents the primary and preferred treatment modality for individuals with localized disease.
  • Radiation therapy is appropriate for the treatment of positive surgical margins or palliation of disease-related symptoms.
  • The treatment of advanced, metastatic disease is particularly challenging given the recognition that conventional chemotherapy has proven to be largely ineffective.
  • Systemic chemotherapy may be considered in variant forms such as mesenchymal or dedifferentiated chondrosarcomas but high-quality data supporting its use is limited.
  • There is universal agreement, however, that novel treatment strategies are desperately needed.
  • [MeSH-major] Bone Neoplasms / therapy. Chondrosarcoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Disease Management. Humans. Palliative Care. Prognosis. Radiography. Radiotherapy, Adjuvant / methods. Therapies, Investigational. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2007 Sep;462:175-80 [17514007.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):859-64 [11484965.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jun;459:40-7 [17414166.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):432-9 [10470818.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):147-52 [17653766.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1630-42 [11701784.001]
  • [Cites] J Bone Joint Surg Am. 2007 Oct;89(10 ):2113-23 [17908885.001]
  • [Cites] Strahlenther Onkol. 1999 Jun;175 Suppl 2:57-63 [10394399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):647-55 [8040010.001]
  • [Cites] J Bone Joint Surg Br. 2005 Nov;87(11):1527-30 [16260673.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):171-7 [17056193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):732-9 [19095372.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):55-61 [10697315.001]
  • [Cites] Neurosurgery. 2004 Dec;55(6):1252-60; discussion 1260-2 [15574207.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):401-9 [16168833.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):591-6 [10837940.001]
  • [Cites] J Surg Oncol. 2002 Oct;81(2):70-4 [12355406.001]
  • [Cites] J Bone Joint Surg Am. 1986 Oct;68(8):1197-205 [3021775.001]
  • [Cites] Radiology. 2000 Feb;214(2):539-46 [10671608.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):420-37 [17442233.001]
  • [Cites] Clin Orthop Relat Res. 2007 Oct;463:166-72 [17632422.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):423-7 [18038872.001]
  • [Cites] Skeletal Radiol. 2005 Jul;34(7):367-74 [15937711.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):223-30 [6703199.001]
  • [Cites] J Bone Joint Surg Am. 2004 Nov;86-A(11):2412-8 [15523011.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jan;84(1):93-9 [11837841.001]
  • [Cites] Cancer. 2008 Jun;112(11):2424-31 [18438777.001]
  • [Cites] Skeletal Radiol. 1991;20(3):187-91 [2057790.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] J Bone Joint Surg Am. 1999 Mar;81(3):326-38 [10199270.001]
  • [Cites] Radiographics. 2003 Sep-Oct;23 (5):1245-78 [12975513.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):189-95 [15129700.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2060-5 [17720491.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jun;459:146-9 [17452919.001]
  • [Cites] Clin Orthop Relat Res. 2001 Oct;(391):224-33 [11603673.001]
  • [Cites] J Am Acad Orthop Surg. 2000 Sep-Oct;8(5):292-304 [11029557.001]
  • [Cites] Sarcoma. 1999;3(2):115-9 [18521273.001]
  • (PMID = 19238552.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


14. Kotil K, Bilge T, Olagac V: Primary intradural myxoid chondrosarcoma: a case report and review in the literature. J Neurooncol; 2005 Nov;75(2):169-72
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intradural myxoid chondrosarcoma: a case report and review in the literature.
  • OBJECTIVE AND IMPORTANCE: Chondrosarcomas are extremely rare cartilaginous tumours that typically usually are associated with bone.
  • Therapeutic experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • We report the first case in the literature of a primary intradural myxoid chondrosarcoma.
  • We could not identify this lesion as chondrosarcoma in preoperative period.
  • The mass was excised completely and microscopic examination identified a myxomatous chondrosarcoma.
  • But a histological examination revealed primary myxoid chondrosarcoma.
  • Experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • CONCLUSION: The differential diagnosis considered in the present case included meningioma, plasmacytoma, and non-neoplastic intradural spinal cord lesion.
  • We emphasize the benefit of surgical resection without radiotherapy and/or chemotherapy.
  • This case presents the first case in the literature of an primary spinal intradural myxoid chondrosarcoma.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Pia Mater / pathology
  • [MeSH-minor] Adult. Dura Mater / surgery. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiography. Time Factors. Treatment Outcome. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):818-31 [890662.001]
  • [Cites] J Neurosurg. 1994 May;80(5):928-30 [8169637.001]
  • [Cites] Surg Neurol. 1989 Jun;31(6):470-2 [2718090.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):828-34 [8636311.001]
  • [Cites] Clin Orthop Relat Res. 1982 Jun;(166):226-32 [7083677.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):420-3 [11220388.001]
  • [Cites] Clin Orthop Relat Res. 1993 Sep;(294):90-5 [8358950.001]
  • [Cites] Spine (Phila Pa 1976). 1978 Sep;3(3):202-9 [715548.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):150-3 [7671456.001]
  • [Cites] Cancer. 1986 Jun 15;57(12 ):2444-53 [3697943.001]
  • (PMID = 16283441.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


15. Benateau H, Rigau V, Martin JP, Labbé D, Compère JF: [Diagnostic difficulties of chondrosarcoma of the jaw. Apropos of a case and review of the literature]. Rev Stomatol Chir Maxillofac; 2000 Apr;101(2):80-5
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties of chondrosarcoma of the jaw. Apropos of a case and review of the literature].
  • [Transliterated title] Difficultés diagnostiques du chondrosarcome des maxillaires. A propos d'un cas et revue de la littérature.
  • Chondrosarcoma is an uncommon malignant mesenchymal tumor characterized by the production of cartilaginous tissue and the absence of production of bone tissue.
  • The clinical and radiographic findings are similar to those seen in other tumors of the jaw, often delaying diagnosis and treatment and subsequently jeopardizing prognosis.
  • In the literature, the mean delay from first clinical signs to diagnosis is about 8 months.
  • As in all tumoral diseases, pathology confirms the diagnosis.
  • We report a case of chondrosarcoma of the maxillary bone and review the literature, focusing on the difficulty in establishing the diagnosis, even at the pathology examination.
  • We propose wide surgical excision, which, in agreement with other reports in the literature, is the only therapeutic possibility.
  • Radiotherapy and chemotherapy may be useful in certain cases.
  • [MeSH-major] Chondrosarcoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone and Bones / pathology. Cartilage / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Mandible / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10859759.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 40
  •  go-up   go-down


16. Mrad K, Sassi S, Smida M, Oubiche F, Mekni A, Romdhane KB: Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. Pathologica; 2004 Dec;96(6):475-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone.
  • BACKGROUND: Primary malignant mesenchymoma of the bone is a rare neoplasm consisting of two or more unrelated malignant mesenchymal components.
  • OBSERVATION: We report an exceedingly rare case of primary malignant mesenchymoma of bone composed of rhabdomyosarcoma, osteosarcoma, and a minor chondrosarcoma component, arising in the right proximal humerus of a 15-year-old girl.
  • The rhabdomyosarcomatous component was present in the initial biopsy and persisted in surgical specimen following chemotherapy.
  • CONCLUSION: Effect of chemotherapy is enigmatic since rhabdomyosarcomatous component could appear, persist or disappear after chemotherapy according to literature.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology. Osteosarcoma / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Antimetabolites, Antineoplastic / therapeutic use. Chondrosarcoma / diagnosis. Chondrosarcoma / drug therapy. Chondrosarcoma / pathology. Chondrosarcoma / radiography. Chondrosarcoma / surgery. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / radiography. Fibrosarcoma / surgery. Humans. Methotrexate / therapeutic use. Neoplasm Proteins / analysis. Osteolysis / etiology. Postoperative Complications / etiology. Pulmonary Embolism / etiology. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant mesenchymoma .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792374.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Desmin; 0 / Neoplasm Proteins; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 12
  •  go-up   go-down


17. Iacobellis C, Olmeda A: The Ilizarov method in the treatment of malignant neoplasms of the tibia. Chir Organi Mov; 2004 Jul-Aug;89(3):245-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ilizarov method in the treatment of malignant neoplasms of the tibia.
  • A total of 3 malignant neoplasms of the tibia are presented: 1 is a mesenchymal chondrosarcoma of the tibial pylon (male aged 14 years), and 2 are cases of squamous skin carcinoma of the leg with tibial infiltration (1 male and 1 female aged 32 and 64 years, respectively).
  • The resections carried out (16.5 cm on the average) were treated by bone transport.
  • At the end of transport a second surgical stage involving astragalotibial arthrodesis was performed in the first case, and revision of the junction site of bone segments transported with application of autoplastic bone grafts was performed in the other two.
  • The regenerate obtained was slowly corticalized in the first patient, submitted to various cycles of chemotherapy during the course of distraction.
  • In the other two cases, which were not treated by chemotherapy during distraction, corticalization occurred over a shorter amount of time.
  • [MeSH-major] Bone Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Chondrosarcoma, Mesenchymal / surgery. Ilizarov Technique. Tibia
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arthrodesis. Bone Transplantation. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Osteogenesis, Distraction. Osteotomy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Time Factors. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751591.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Domoto H, Mano Y, Kita T, Kikuchi Y, Sato K, Aida S, Tamai S: Chondrosarcomatous differentiation in metastatic deposit of serous papillary cystadenocarcinoma. Pathol Int; 2000 Jun;50(6):497-501
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis was serous papillary cystadenocarcinoma of both ovaries with lymph node metastasis.
  • After six courses of chemotherapy, she was confirmed to be in complete remission following a second laparotomy.
  • Following additional chemotherapy, a third laparotomy disclosed swollen left inguinal lymph nodes.
  • In one of these nodes, approximately 5.0 cm in greatest diameter, the predominant histological features were: chondrosarcoma of the bone and soft tissue, with small foci of serous papillary adenocarcinoma and squamous epithelium.
  • A histological transition between mesenchymal and epithelial areas was identified.
  • [MeSH-major] Chondrosarcoma / pathology. Cystadenocarcinoma, Papillary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymphatic Metastasis. Middle Aged. Mucin-1 / analysis. S100 Proteins / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Papillary cystadenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886727.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Mucin-1; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


19. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA: Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol; 2007 Jun;8(6):513-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunities for improving the therapeutic ratio for patients with sarcoma.
  • Sarcomas are mesenchymal cancers, which, in many cases, have distinctive molecular features.
  • Limb-sparing surgery delivered at specialised sarcoma centres as part of a multidisciplinary approach has become the standard treatment for most patients and usually provides excellent local control.
  • Preoperative treatment with chemotherapy is most common for patients with bone sarcomas.
  • The ideal sequence of surgery and radiation for local management of soft-tissue sarcoma remains controversial on the basis of early versus late treatment complications, although preoperative radiation can provide the best results for improved long-term function.
  • However, metastatic disease is common, and conventional chemotherapy provides for only a narrow therapeutic window outside of a few responsive pathological subtypes.
  • Targeting underlying molecular events in specific sarcomas can provide for dramatic benefits, as has been seen with imatinib treatment for gastrointestinal stromal tumours and dermatofibrosarcoma protuberans.
  • Trials of agents targeting the cell cycle and angiogenesis in soft-tissue sarcomas, and of those targeting osteoclasts in bone sarcomas, are currently underway.
  • Biological data and preclinical studies support trials using inhibitors of hedgehog signalling in chondrosarcoma, inhibitors of wnt/beta-catenin in osteosarcoma and aggressive fibromatosis, and inhibitors of histone deacetylases in synovial sarcoma and Ewing sarcoma.
  • Research in stem-cell biology and nanotechnology holds promise for additional novel treatment options in the future.
  • [MeSH-major] Bone Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Aug;8(8):667-8; author reply 668-9 [17679078.001]
  • [ErratumIn] Lancet Oncol. 2007 Aug;8(8):670
  • (PMID = 17540303.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 92
  •  go-up   go-down


20. Postovsky S, Ash S, Ramu IN, Yaniv Y, Zaizov R, Futerman B, Elhasid R, Ben Barak A, Halil A, Ben Arush MW: Central nervous system involvement in children with sarcoma. Oncology; 2003;65(2):118-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From 1990 to 2001, all medical charts were retrospectively reviewed: 19 sarcoma patients (12 boys and 7 girls) were diagnosed with CNSI (4 osteogenic sarcomas, 11 Ewing sarcomas, 2 rhabdomyosarcomas, 1 alveolar soft part sarcoma and 1 mesenchymal chondrosarcoma).
  • Mean age of all patients at the time of initial diagnosis was 14.9 years (range: 4-24 years), mean age at the time when CNSI was diagnosed was 16.9 years (range: 5.5-27 years).
  • The mean duration of time elapsed since diagnosis of CNSI till death or last follow-up was 5.2 months (SD: +/-5.7 months).
  • Four patients received chemotherapy (CT) alone, 8 CT and radiotherapy (RT), 2 RT alone, 3 supportive treatment only, 1 CT and surgery and 1 surgery alone.
  • Sixteen patients died; there was no significant difference in the duration of survival between those who were treated with RT or surgery (mean +/- SD: 6.77 +/- 6.56 months) and those who received only CT or supportive treatment (mean +/- SD: 2.60 +/- 2.94 months) (p = 0.07).
  • Brain disease was the main cause of death in all but 1 patient who died 4 days after autologous bone marrow transplantation from uncontrolled sepsis.
  • More effective therapy has to be developed in order to improve their outcome.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Israel / epidemiology. Male. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12931017.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Aksoy S, Abali H, Kiliçkap S, Güler N: Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma. J Neurooncol; 2005 Feb;71(3):333-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Neoplasms / drug therapy. Brain Neoplasms / drug therapy. Chondrosarcoma, Mesenchymal / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Resistance, Neoplasm / drug effects. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2000 Jan;46(1):207-11; discussion 211-2 [10626952.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):249-54 [11300333.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3644-50 [12202665.001]
  • [Cites] J Craniomaxillofac Surg. 1997 Dec;25(6):322-7 [9504309.001]
  • [Cites] Med Pediatr Oncol. 1984;12(4):264-6 [6205246.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):461-4 [10070455.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):161-3 [7900708.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):88-92 [9667567.001]
  • (PMID = 15735926.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down






Advertisement